Literature DB >> 16487016

Aggressiveness of therapy and prognosis of patients with Hürthle cell papillary thyroid carcinoma.

N Besic1, M Hocevar, J Zgajnar, R Petric, G Pilko.   

Abstract

Hürthle cell papillary thyroid carcinoma (HCPTC) has been studied separately from other types of thyroid carcinoma in relatively few studies. The aim of our study was to determine the factors associated with the survival of patients with HCPTC in Slovenia, an iodine-deficient region. A total of 1552 patients with thyroid carcinoma were seen at our institute during the period of 1976-2003; of them, 42 patients (33 females, 9 males; age 10-85 years, median 56.5 years) had histopathologically verified HCPTC. The data on the patients' gender, age, disease history, extent of disease, morphologic characteristics, therapy, locoregional control, disease-free interval, and survival were collected. The statistical correlation between possible prognostic factors and the disease-free interval and survival was analyzed by chi2 test and log rank analysis. The tumor diameter ranged from 1 to 9 cm (median, 3 cm). Extrathyroid tumor growth was found in 19 patients, lymph node metastases in 13 patients, and distant metastases in 2 patients. Primary treatment consisted of total or near-total thyroidectomy (39 patients), lobectomy (2 patients), radioiodine ablation of the thyroid remnant (37 patients), external irradiation (14 patients), and chemotherapy (3 patients). Locoregional recurrence was diagnosed in four patients, and dissemination in 1 patient during the follow-up period of 0.75-20 years (median, 5.5 years). Three patients died of thyroid carcinoma during the follow-up period. The 5-year and 10-year survivals were 94% and 87%, respectively. The 5-year and 10-year disease-free intervals were 93% and 81%, respectively. The factors correlated with the survival were: age, extrathyroid tumor growth, primary tumor stage, and regional and distant metastases. Although extrathyroidal tumor growth was found in 45% of the patients with HCPTC, our patients had a favorable prognosis. Long-term survival and locoregional control of disease are likely after the radical tumor resection, radioiodine ablation of the thyroid remnant, and external irradiation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16487016     DOI: 10.1089/thy.2006.16.67

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  9 in total

1.  Hürthle Cell Carcinoma: Single Center Analysis and Considerations for Surgical Management Based on the Recent Literature.

Authors:  Costanza Chiapponi; Milan J M Hartmann; Matthias Schmidt; Michael Faust; Christiane J Bruns; Anne M Schultheis; Hakan Alakus
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-29       Impact factor: 6.055

2.  Older age and larger tumor size predict malignancy in hürthle cell neoplasms of the thyroid.

Authors:  Yi Wei Zhang; David Yu Greenblatt; Daniel Repplinger; Anna Bargren; Joel T Adler; Rebecca S Sippel; Herbert Chen
Journal:  Ann Surg Oncol       Date:  2008-07-30       Impact factor: 5.344

Review 3.  German Association of Endocrine Surgeons practice guideline for the surgical management of malignant thyroid tumors.

Authors:  Henning Dralle; Thomas J Musholt; Jochen Schabram; Thomas Steinmüller; Andreja Frilling; Dietmar Simon; Peter E Goretzki; Bruno Niederle; Christian Scheuba; Thomas Clerici; Michael Hermann; Jochen Kußmann; Kerstin Lorenz; Christoph Nies; Peter Schabram; Arnold Trupka; Andreas Zielke; Wolfram Karges; Markus Luster; Kurt W Schmid; Dirk Vordermark; Hans-Joachim Schmoll; Reinhard Mühlenberg; Otmar Schober; Harald Rimmele; Andreas Machens
Journal:  Langenbecks Arch Surg       Date:  2013-03-03       Impact factor: 3.445

4.  Recombinant human thyrotropin-aided radioiodine therapy in patients with metastatic differentiated thyroid carcinoma.

Authors:  Ivana Zagar; Andreja A Schwarzbartl-Pevec; Barbara Vidergar-Kralj; Rika Horvat; Nikola Besic
Journal:  J Thyroid Res       Date:  2011-08-18

5.  Prognostic factors for disease-specific survival in 108 patients with Hürthle cell thyroid carcinoma: a single-institution experience.

Authors:  Rok Petric; Barbara Gazic; Nikola Besic
Journal:  BMC Cancer       Date:  2014-10-23       Impact factor: 4.430

6.  Treatment and outcome of 32 patients with distant metastases of Hürthle cell thyroid carcinoma: a single-institution experience.

Authors:  Nikola Besic; Andreja Schwarzbartl-Pevec; Barbara Vidergar-Kralj; Tea Crnic; Barbara Gazic; Maja Marolt Music
Journal:  BMC Cancer       Date:  2016-02-26       Impact factor: 4.430

7.  Expression of Autophagy-Related Proteins in Hürthle Cell Neoplasm Is Different from That in Follicular Neoplasm.

Authors:  Yoon Jin Cha; Hye Min Kim; Ja Seung Koo
Journal:  Dis Markers       Date:  2017-07-27       Impact factor: 3.434

8.  Oncocytic Papillary Thyroid Carcinoma and Oncocytic Poorly Differentiated Thyroid Carcinoma: Clinical Features, Uptake, and Response to Radioactive Iodine Therapy, and Outcome.

Authors:  Jelena Lukovic; Irina Petrovic; Zijin Liu; Susan M Armstrong; James D Brierley; Richard Tsang; Jesse D Pasternak; Karen Gomez-Hernandez; Amy Liu; Sylvia L Asa; Ozgur Mete
Journal:  Front Endocrinol (Lausanne)       Date:  2021-12-16       Impact factor: 5.555

9.  Expression of miRNA and Occurrence of Distant Metastases in Patients with Hürthle Cell Carcinoma.

Authors:  Rok Petric; Barbara Gazic; Katja Goricar; Vita Dolzan; Radan Dzodic; Nikola Besic
Journal:  Int J Endocrinol       Date:  2016-07-28       Impact factor: 3.257

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.